Some clinical studies and some preclinical evidence suggest that NF2 inactivation might be associated with response to mTOR inhibitors.[47, 48] Everolimus and temsirolimus are both mTOR inhibitors and have been approved by the FDA for the treatment of neuroendocrine tumors of the gastro-intestinal tract or lung, HER2/neu-negative breast cancer and renal cell carcinoma, among others. The gene discussed is MTOR; the disease is hereditary clear cell renal cell carcinoma.